Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB) confirmed Thursday its subsidiary Aurora Germany GmbH has extended its collaboration with a United Kingdom-focused biopharmaceutical company Grow Group PLC. The two companies signed a two-year market access services agreement for the U.K.
Previously, the Canadian cannabis giant was one of the first companies to partner with Grow Group in August 2019. Since its original partnership, both companies are said to have dominated the U.K. medical cannabis market.
"We are delighted to extend our existing strategic relationship with Grow," Miguel Martin, CEO of Aurora Cannabis stated. "We have worked successfully with Grow and their joint venture partner, IPS, since entering the UK market.
“Renewing this agreement will help to broaden access for patients by leveraging Grow's work educating physicians and creating awareness of medical cannabis options. Aurora is committed to providing …